Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | The importance of diagnosing DLBCL on a molecular level and how it will improve treatment

Georg Lenz • 9 Jun 2016
EHA 2016
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Non-Hodgkin Lymphoma

Georg Lenz, MD, PhD, from the University of Münster, Münster, Germany discusses the clinical significance of diagnosing diffuse large B-cell lymphoma (DLBCL) on a molecular level at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Prof. Lenz mentions how treatment can become specific by utilizing genetics and introducing novel inhibitors that target specific signaling pathways. He holds the optimism that this can improve survival for affected patients.

More from Georg Lenz

1:29
Update from the Lenz lab in Münster
Georg Lenz • 20 Jun 2019
0:55
DLBCL research to watch
Georg Lenz • 20 Jun 2019
1:26
Can we improve on R-CHOP for the frontline treatment of DLBCL?
Georg Lenz • 20 Jun 2019
0:43
The unmet need in DLBCL
Georg Lenz • 18 Apr 2016

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals